Interactions with the Human Body

Adverse Effects of Engineered Nanomaterials

Volumn , Issue , 2012, Pages 3-24

  Colognato, Renato ^a   Park, Margriet V D Z ^b,c   Wick, Peter ^d   De Jong, Wim H ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882771664     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386940-1.00001-5     Document Type: Chapter

References (146)

1. Speiser P., Khanna S.C. Perlpolymerisate, eine neue perorale Darreichungsform und ihre Beeinflussung durch Arzneistoffe. Praepar Pharm 1970, 6:1-4.
2. Zolle I., Hosein F., Rhodes B.A.T.K., Wagner H.N. Human serum albumin microspheres for studies of the reticuloendothelial system. J Nucl Med 1973, 11:379.
3. Scheffel U., Rhodes B.A., Natarajan T.K., Wagner H.N. Albumin microspheres for study of the reticuloendothelial system. J Nucl Med 1973, 13:498-503.
4. Kramer P.A. Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 1974, 63:1646-1647.
5. Sugibayashi K., Morimoto Y., Nadai T., Kato Y., Hasegawa A., Arita T. Drug-carrier property of albumin microspheres in chemotherapy. II. Preparation and tissue distribution in mice of microsphere-entrapped 5- fluorouracil. Chem Pharm Bull 1979, 27:204-209.
6. Nanotechnology-Vocabulary-Part 1. Core terms 2010, ISO/TS 80004-1, International Organization for Standardization (ISO), Geneva, Switzerland.
7. Opinion on the scientific basis for the definition of the term "nanomaterial", 8 December 2010 2010, SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), European Commission, Brussels, Belgium. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_032.pdf.
8. Interim policy statement on Health Canada's working definition for nanomaterials; 2010 2010, Health Canada, Available from: URL. http://www.hc-sc.gc.ca/sr-sr/alt_formats/pdf/consult/_2010/nanomater/dra ft-ebauche-eng.pdf.
9. OECD Working Party on Manufactured Nanomaterials. Guidance for the use of the OECD database on research into the safety of manufactured nanomaterials 2008, OECD, Ver 1 October 2008. Available from: URL. http://www.oecd.org/dataoecd/21/19/44033847.pdf.
10. Guidance on new chemical requirements for notification of industrial nanomaterials 2010, NICNAS, (National Industrial Chemicals Notification and Assessment Scheme)(National Industrial Chemicals Notification and Assessment Scheme), Available from URL. http://www.nicnas.gov.au/Current_Issues/Nanotechnology/Guidance%20on%20N ew%20Ch%20.
11. FDA (Food and Drug Administration) Draft Guidance: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology 2011, US Food and Drug Administration, Silver Spring, MD, USA. http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm25792 6.htm.
12. European Commission Official Journal of the European Commission L342/59. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products 2009, European Commission, Brussels, Belgium, L:2009:342:0059:0209:EN: PDF. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do%3Furi%3D%20OJ.
13. Auffan M., Rose J., Bottero J.-Y., Lowry G.V., Jolivet J.-P., Wiesner M.R. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009, 4:634-641.
14. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
15. Buzea C., Pachecob I.I., Robbie K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases 2007, 4:MR17-MR70.
16. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-839.
17. Tarantola M., Pietuch A., Schneider D., et al. Toxicity of gold-nanoparticles: Synergistic effects of shape and surface functionalization on micromotility of epithelial cells. Nanotoxicology 2010, 5:254-268.
18. Tsuji J.S., Maynard A.D., Howard P.C., et al. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Sci 2006, 89:42-50.
19. Borm P.J., Robbins D., Haubold S., et al. The potential risks of nanomaterials: A review carried out for ECETOC. Part Fibre Toxicol 2006, 14:3-11.
20. Wick P., Manser P., Limbach L.K., et al. The degree and kind of agglomeration affect carbon nanotube cytotoxicity. Toxicol Lett 2007, 168:121-131.
21. Schaeublin N.M., Braydich-Stolle L.K., Schrand A.M., et al. Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale 2011, 3:410-420.
22. Carlson C., Hussain S.M., Schrand A.M., et al. Unique cellular interaction of silver nanoparticles: Size-dependent generation of reactive oxygen species. J Phys Chem B 2008, 112:13608-13619.
23. Pal S., Tak Y.K., Song J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007, 73:1712-1720.
24. El Badawy A.M., Silva R.G., Morris B., Scheckel K.G., Suidan M.T., Tolaymat T.M. Surface charge-dependent toxicity of silver nanoparticles. Environ Sci Technol 2011, 45:283-287.
25. Kvitek L., Vanickova M., Panacek A., et al. Initial study on the toxicity of silver nanoparticles (NPs) against Paramecium caudatum. J Phys Chem C 2009, 113:4296-4300.
26. Johnston H.J., Hutchison G.R., Christensen F.M., Aschberger K., Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci 2010, 114:162-182.
27. Johnston H.J., Hutchison G.R., Christensen F.M., et al. A critical review of the biological mechanisms underlying the in vivo and in vitro toxicity of carbon nanotubes: The contribution of physico-chemical characteristics. Nanotoxicology 2010, 4:207-246.
28. Nel A.E., Mädler L., Velegol D., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
29. Lynch I., Dawson K.A. Protein-nanoparticle interactions. Nano Today 2008, 3:40-47.
30. Cedervall T., Lynch I., Lindman S., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007, 104:2050-2055.
31. Lynch I., Salvati A., Dawson K.A. Protein-nanoparticle interactions: What does the cell see?. Nat Nanotechnol 2009, 4:546-547.
32. Mu Q., Liu W., Xing Y., et al. Protein binding by functionalized multiwalled carbon nanotubes is governed by the surface chemistry of both parties and the nanotube diameter. J Phys Chem 2008, 112:3300-3307.
33. Wasdo S.C., Barber D.S., Denslow N.D., et al. Differential binding of serum proteins to nanoparticles. Int J Nanotechnol 2008, 5:92-115.
34. Dutta D., Sundaram S.K., Teeguarden J.G., et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci 2007, 100:303-315.
35. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008, 105:14265-14270.
36. Bertolazzi P., Guerra C., Liuzzi G. A global optimization algorithm for protein surface alignment. BMC Bioinformatics 2010, 11:488.
37. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modelling the time evolution of the nanoparticle-protein corona in a body fluid. PloS one 2010, 5:e10949.
38. Cabaleiro-Lago C., Lynch I., Dawson K.A., Linse S. Inhibition of IAPP and IAPP(20-29) fibrillation by polymeric nanoparticles. Langmuir 2010, 26:3453-3461.
39. Linse S., Cabaleiro-Lago C., Xue W.F., et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci USA 2007, 104:8691-8696.
40. Krug H.F., Wick P. Nanotoxicology: An interdisciplinary challenge. Angew Chem Int Ed Engl 2011, 50:1260-1278.
41. Gasser M., Rothen-Rutishauser B., Krug H.F., et al. The adsorption of biomolecules to multi-walled carbon nanotubes is influenced by both pulmonary surfactant lipids and surface chemistry. J Nanobiotechnol 2010, 8:31.
42. Schleh C., Rothen-Rutishauser B., Kreyling W.G. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm 2011, 77:350-352.
43. Hofmann-Amtenbrink M., Hofmann H., Montet X. Superparamagnetic nanoparticles-a tool for early diagnostics. Swiss Med Wkly 2010, 140:w13081.
44. Li J., Zhang C., Yang K., Liu P., Xu L.X. SPIO-RGD nanoparticles as a molecular targeting probe for imaging tumor angiogenesis using synchrotron radiation. J Synchrotron Radiat 2011, 18:612-616.
45. Beyersmann D., Hartwig A. Carcinogenic metal compounds: Recent insight into molecular and cellular mechanisms. Arch Toxicol 2008, 82:493-512.
46. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
47. Limbach L.K., Wick P., Manser P., Grass R.N., Bruinink A., Stark W.J. Exposure of engineered nanoparticles to human lung epithelial cells: Influence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol 2007, 41:4158-4163.
48. Geiser M., Rothen-Rutishauser B., Kapp N., et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 2005, 113:1555-1560.
49. Limbach L.K., Li Y., Grass R.N., et al. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ Sci Technol 2005, 39:9370-9376.
50. Oberdorster G., Maynard A., Donaldson K., et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2005, 2:8.
51. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
52. Kanno S., Furuyama A., Hirano S. A murine scavenger receptor MARCO recognizes polystyrene nanoparticles. Toxicol Sci 2007, 97:398-406.
53. Rothen-Rutishauser B.M., Schurch S., Haenni B., Kapp N., Gehr P. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol 2006, 40:4353-4359.
54. George S., Pokhrel S., Xia T., et al. Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano 2010, 4:15-29.
55. Xia T., Kovochich M., Liong M., et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano 2008, 2:2121-2134.
56. Xia T., Zhao Y., Sager T., et al. Decreased dissolution of ZnO by iron doping yields nanoparticles with reduced toxicity in the rodent lung and zebrafish embryos. ACS Nano 2011, 5:1223-1235.
57. Kocbach A., Li Y., Yttri K.E., Cassee F.R., Schwarze P.E., Namork E. Physicochemical characterisation of combustion particles from vehicle exhaust and residential wood smoke. Part Fibre Toxicol 2006, 3:1.
58. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 2010, 267:89-105.
59. Semmler-Behnke M., Kreyling W.G., Lipka J., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
60. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Del Rev 2009, 61:428-437.
61. Dobrovolskaia M.A., Patri A.K., Zheng J., et al. Interaction of colloidal gold nanoparticles with human blood: Effects on particle size and analysis of plasma protein binding profiles. Nanomed Nanotechnol Biol Med 2009, 5:106-117.
62. Lacerda S.H., Park J.J., Meuse C., et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 2010, 4:365-379.
63. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J.A.M., Geertsma R.E. Particle size dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
64. Demoy M., Gibaud S., Andreux J.P., Weingarten C., Gouritin B., Couvreur P. Splenic trapping of nanoparticles: Complementary approaches for in situ studies. Pharm Res 1997, 14:463-468.
65. Sadauskas E., Wallin H., Stoltenberg M., et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 2007, 4:10.
66. Lipka J., Semmler-Behnke M., Sperling R.A., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31:6574-6581.
67. Lankveld D.P.K., Oomen A.G., Krystek P., et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 2010, 31:8350-8361.
68. Lankveld D.P.K., Rayavarapu R.G., Krystek P., et al. Blood clearance and tissue distribution of pegylated and non-pegylated gold nanorods after intravenous administration in rats. Nanomedicine 2011, 6:339-349.
69. Weissenbrock A., Wirth M., Gabor F. WGA grafted PLGA-nanospheres: Preparation and association with Caco-2 cells. J Contr Release 2004, 99:383-392.
70. Nobs L., Buchegger F., Gurny R., Allémann E. Poly(lactic acid) nanoparticles labeled with biologically active NeutravidinTM for active targeting. Eur J Pharm Biopharm 2004, 58:483-490.
71. Prinzen L., Miserus R.J., Dirksen A., et al. Optical and magnetic resonance imaging of cell death and platelet activation using annexin A5-functionalized quantum dots. Nano Lett 2007, 7:93-100.
72. Akiyama Y., Mori T., Katayama Y., Niidome T. The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor bearing mice. J Contr Release 2009, 139:81-84.
73. Von Maltzahn G., Park J.-H., Agrawal A., et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009, 69:3892-3900.
74. Balogh L., Nigavekar S.S., Nair B.M., et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed Nanotechnol Biol Med 2007, 3:281-296.
75. Wang F.H., Kim D.K., Yoshitake T., et al. Diffusion and clearance of superparamagnetic iron oxide nanoparticles infused into the rat striatum studied by MRI and histochemical techniques. Nanotechnology 2011, 22. 015103.
76. Hirn S., Semmler-Behnke M., Schleh K., et al. Particle size dependent and surface charge dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407-416.
77. Wick P., Malek A., Manser P., et al. Barrier capacity of human placenta for nanosized materials. Environ Heath Perspect 2010, 118:432-436.
78. Choi H.S., Liu W., Misra P., et al. Renal clearance of quantum dots. Nat Biotech 2007, 25:1165-1170.
79. Kreyling W.G., Semmler M., Erbe F., et al. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health, Part A 2002, 65:1513-1530.
80. Ji J.H., Jung J.H., Kim S.S., et al. Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2007, 19:857-871.
81. Sung J.H., Ji J.H., Park J.D., et al. Subchronic inhalation toxicity of gold nanoparticles. Part Fibre Toxicol 2011, 8:16.
82. Yu L.E., Yung L.-Y.L., Ong C.-N., et al. Translocation and effects of gold nanoparticles after inhalation exposure in rats. Nanotoxicology 2007, 1:235-242.
83. Pauluhn J. Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminum oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): The key metric of dose is particle mass and not particle surface area. Toxicology 2009, 259:140-148.
84. Pauluhn J. Poorly soluble particulates: Searching for a unifying denominator of nanoparticles and fine particles for DNEL estimation. Toxicology 2011, 279:176-188.
85. Bowman K., Leong K.W. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 2006, 1:117-128.
86. Muchow M., Maincent P., Muller R.H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008, 34:1394-1405.
87. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
88. Jani P., Halbert G.W., Langridge J., Florence A.T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1990, 42:821-826.
89. Wang J., Zhoua G., Chena C., et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 2007, 168:176-185.
90. Kim Y.S., Kim J.S., Cho H.S., et al. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley Rats. Inhal Toxicol 2008, 20:575-583.
91. Park E.J., Yi J., Kim Y., Choi K., Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol In Vitro 2010, 24:872-878.
92. Park E.J., Bae E., Yi J., et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ Toxicol Pharmacol 2010, 30:162-168.
93. Jani P.U., McCarthy D.E., Florence A.T. Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. Int J Pharmaceut 1994, 105:157-168.
94. Ryman-Rasmussen J., Riviere J.E., Monteiro-Riviere N.A. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci 2006, 91:159-165.
95. Wu J., Liu W., Xue C., et al. Toxicity and penetration of TiO2 nanoparticles in hairless mice and porcine skin after subchronic dermal exposure. Toxicol Lett 2009, 191:1-8.
96. Larese Filon F., Crosera M., Adami G., Bovenzi M., Rossi F., Maina G. Human skin penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology 2011, (in press).
97. Smijs T.G., Bouwstra J.A. Focus on skin as a possible port of entry for solid nanoparticles and the toxicological impact. J Biomed Nanotechnol 2010, 6:469-484.
98. Nabeshi H., Yoshikawa T., Matsuyama K., et al. Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials 2011, 32:2713-2724.
99. Tang J., Xiong L., Wang S., et al. Distribution, translocation and accumulation of silver nanoparticles in rats. J Nanosci Nanotechnol 2009, 9:4924-4932.
100. Gulson B., McCall M., Korsch M., et al. Small amounts of zinc from zinc oxide particles in sunscreens applied outdoors are absorbed through human skin. Tox Sci 2010, 118:140-149.
101. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
102. De Jong W.H., Borm P.J.A. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed 2008, 3:133-149.
103. Irache J.M., Esparza I., Gamazo C., Agüeros M., Espuelas S. Nanomedicine: Novel approaches in human and veterinary therapeutics. Vet Parasitol 2011, doi:10.1016/j.vetpar.2011.05.028.
104. Wijnhoven S.W.P., Peijnenburg W.J.G.M., Herberts C.A., et al. Nano-silver-a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 2009, 3:109-138.
105. Dimkpa C.O., Calder A., Britt D.W., McLean J.E., Anderson A.J. Responses of a soil bacterium, Pseudomonas chlororaphis O6 to commercial metal oxide nanoparticles compared with responses to metal ions. Environ Pollut 2011, 159:1749-1756.
106. Park E.J., Yi J., Kim Y., Choi K., Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol In Vitro 2010, 24:872-878.
107. Fabian E., Landsiedel R., Ma-Hock L., Wiench K., Wohlleben W., Van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 2008, 82,151-157.
108. Park M.V.D.Z., Lankveld D.P.K., van Loveren H., de Jong W. The status of in vitro toxicity studies in risk assessment of nanomaterials. Nanomedicine 2009, 4:669-685.
109. Ayres J.G., Borm P., Cassee F.R., et al. Evaluating the toxicity of airborne particulate matter and nanoparticles by measuring oxidative stress potential-a workshop report and consensus statement. Inhal Toxicol 2008, 20:75-99.
110. Madl A.K., Pinkerton K.E. Health effects of inhaled engineered and incidental nanoparticles. Crit Rev Toxicol 2009, 39:629-658.
111. Napierska D., Thomassen L.C., Lison D., Martens J.A., Hoet P.H. The nanosilica hazard: Another variable entity. Part Fibre Toxicol 2010, 7:39.
112. Cho W.S., Duffin R., Poland C.A., et al. Metal oxide nanoparticles induce unique inflammatory footprints in the lung: Important implications for nanoparticle testing. Environ Health Perspect 2010, 118:1699-1706.
113. Hsiao I.L., Huang Y.J. Effects of various physicochemical characteristics on the toxicities of ZnO and TiO nanoparticles toward human lung epithelial cells. Sci Total Environ 2011, 409:1219-1228.
114. Kasper J., Hermanns M.I., Bantz C., et al. Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures. Part Fibre Toxicol 2011, 8:6.
115. Sager T.M., Castranova V. Surface area of particle administered versus mass in determining the pulmonary toxicity of ultrafine and fine carbon black: Comparison to ultrafine titanium dioxide. Part Fibre Toxicol 2009, 6:15.
116. Sung J.H., Ji J.H., Park J.D., et al. Subchronic inhalation toxicity of silver nanoparticles. Toxicol Sci 2009, 108:452-461.
117. Gosens I., Post J.A., De la Fonteyne L.J.J., et al. Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation. Part Fiber Toxicol 2011, 7:37.
118. Duffin R., Tran L., Brown D., Stone V., Donaldson K. Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: Highlighting the role of particle surface area and surface reactivity. Inhal Toxicol 2007, 19:849-856.
119. Warheit D.B. Debunking some misconceptions about nanotoxicology. Nano Lett 2010, 10:4777-4782.
120. NIOSH Occupational exposure to titanium dioxide. Current Intellegence Bulletin 63. Department of Health and Human Services, Public Health Service Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, (NIOSH), DHHS (NIOSH) Publication No 2011-160. Cincinnati, USA 2011, http://www.cdc.gov/niosh/docs/2011-160/pdfs/2011-160.pdf.
121. de Haar C., Hassing I., Bol M., Bleumink R., Pieters R. Ultrafine but not fine particulate matter causes airway inflammation and allergic airway sensitization to co-administered antigen in mice. Clin Exp. Allergy 2006, 36:1469-1479.
122. Inoue K., Takano H. Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation. Sci World J 2011, 11:382-390.
123. Mitchell L.A., Lauer F.T., Burchiel S.W., McDonald J.D. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol 2009, 4:451-456.
124. McNeil S.E. Nanoparticle therapeutics: A personal perspective. Rev Nanomed Nanobiotechnol 2009, 1:264-271.
125. Hahn M.A., Singh A.K., Sharma P., Brown S.C., Moudgil B.M. Nanoparticles as contrast agents for in-vivo bioimaging: Current status and future perspectives. Anal Bioanal Chem 2011, 399:3-27.
126. Colognato R., Bonelli A., Ponti J., et al. Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro. Mutagenesis 2008, 23:377-382.
127. Migliore L., Saracino D., Bonelli A., et al. Carbon nanotubes induce oxidative DNA damage in RAW 264.7 cells. Environ Mol Mutagen 2010, 51:294-303.
128. Gonzalez L., Lison D., Kirsch-Volders M. Genotoxicity of engineered nanomaterials: A critical review. Nanotoxicology 2008, 2:252-273.
129. Landsiedel R., Kapp M.D., Schulz M., Wiench K., Oesch F. Genotoxicity investigations on nanomaterials: methods, preparation and characterization of test material, potential artifacts and limitations-many questions, some answers. Mutat Res 2009, 681:241-258.
130. Singh N., Manshian B., Jenkins G.J., et al. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891-3914.
131. Ema M., Kobayashi N., Naya M., Hanai S., Nakanishi J. Reproductive and developmental toxicity studies of manufactured nanomaterials. Reprod Toxicol 2010, 30:343-352.
132. Hougaard K.S., Fadeel B., Gulumian M., Kagan V.E., Savolainen K. Developmental toxicity of engineered nanoparticles. Reproductive and developmental toxicology 2011, Elsevier, London. R.C. Gupta (Ed.).
133. Hougaard K.S., Jackson P., Jensen K.A., et al. Effects of prenatal exposure to surface-coated nanosized titanium dioxide (UV-Titan). A study in mice. Part Fibre Toxicol 2010, 7:16.
134. Simko M., Mattsson M.O. Risks from accidental exposures to engineered nanoparticles and neurological health effects: A critical review. Part Fibre Toxicol 2010, 7:42.
135. Brook R.D., Rajagopalan S., Pope C.A., et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010, 121:2331-2378.
136. Shah P.S., Balkhair T. Air pollution and birth outcomes: A systematic review. Environ Int 2011, 37:498-516.
137. Xia T., Li N., Nel A.E. Potential health impact of nanoparticles. Annu Rev Publ Health 2009, 30:137-150.
138. Xia T., Kovochich M., Brant J., et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 2006, 6:1794-1807.
139. Studer A.M., Limbach L.K., Van Duc L., et al. Nanoparticle cytotoxicity depends on intracellular solubility: Comparison of stabilized copper metal and degradable copper oxide nanoparticles. Toxicol Lett 2010, 197:169-174.
140. Shi Y., Zhang J.H., Jiang M., Zhu L.H., Tan H.Q., Lu B. Synergistic genotoxicity caused by low concentration of titanium dioxide nanoparticles and p, p'-DDT in human hepatocytes. Environ Mol Mutagen 2010, 51:192-204.
141. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
142. Donaldson K., Poland C.A., Schins R.P. Possible genotoxic mechanisms of nanoparticles: criteria for improved test strategies. Nanotoxicology 2010, 4:414-420.
143. Donaldson K., Murphy F., Duffin R., Poland C. Asbestos, carbon nanotubes and the pleural mesothelium: A review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010, 7:5.
144. Donaldson K. The inhalation toxicology of p-aramid fibrils. Crit Rev Toxicol 2009, 39:487-500.
145. Ryman-Rasmussen J.P., Cesta M.F., Brody A.R., et al. Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol 2009, 4:747-751.
146. Maynard A.D., Baron P.A., Foley M., Shvedova A.A., Kisin E.R., Castranova V. Exposure to carbon nanotube material: Aerosol release during the handling of unrefined single-walled carbon nanotube material. J Toxicol Environ Health A 2004, 67:87-107.